Compare YieldMax NVDA Option Income Strategy ETF (NVDY) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax NVDA Option Income Strategy ETF vs Recursion Pharmaceuticals Inc — how do they compare? YieldMax NVDA Option Income Strategy ETF trades at $12.78 (market cap $1.45B), while Recursion Pharmaceuticals Inc trades at $4.02 (market cap $2.14B). The key difference: Recursion Pharmaceuticals Inc is the larger of the two by market cap, and Recursion Pharmaceuticals Inc is more actively traded (30,789,535 versus 1,943,739). Which is the better fit depends on your goals — on Pluang, investors hold YieldMax NVDA Option Income Strategy ETF for 43 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| NVDY | RXRX | |
|---|---|---|
Market Cap | $1.45B | $2.14B |
Volume | 1,943,739 | 30,789,535 |
Sector | Income / Options Overlay | Health |
52-Week High | $17.21 | $6.79 |
52-Week Low | $11.58 | $2.84 |
Typical Hold Time | 43 Days | 22 Days |
Enterprise Value | — | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDY, the YieldMax NVDA Option Income Strategy ETF, trades at $13.01, down slightly by 0.31% on the day. The technical outlook is bullish based on moving averages, though oscillators are neutral and RSI levels suggest overbought conditions. The fund generates weekly dividend distributions, with recent payouts ranging from $0.08 to $0.12, but faces criticism for potential net asset value erosion and capped upside participation relative to its underlying asset, NVIDIA stock.
The outlook for NVDY is mixed; it offers high distribution yields but structural limitations may hinder long-term capital appreciation. Investment opportunities include income generation in a low-volatility environment, while risks involve NAV erosion and reduced upside capture if NVIDIA's volatility declines. Analyst sentiment has shifted to hold ratings, reflecting concerns over sustainability.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
